HUE050406T2 - Nagy affinitású PD-1 hatóanyag és alkalmazási módszerek - Google Patents

Nagy affinitású PD-1 hatóanyag és alkalmazási módszerek

Info

Publication number
HUE050406T2
HUE050406T2 HUE15829652A HUE15829652A HUE050406T2 HU E050406 T2 HUE050406 T2 HU E050406T2 HU E15829652 A HUE15829652 A HU E15829652A HU E15829652 A HUE15829652 A HU E15829652A HU E050406 T2 HUE050406 T2 HU E050406T2
Authority
HU
Hungary
Prior art keywords
agents
methods
high affinity
affinity
Prior art date
Application number
HUE15829652A
Other languages
English (en)
Inventor
Aaron Michael Ring
Andrew Kruse
Aashish Manglik
Irving L Weissman
Roy Louis Maute
Melissa N Mccracken
Sydney Gordon
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of HUE050406T2 publication Critical patent/HUE050406T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
HUE15829652A 2014-08-08 2015-08-07 Nagy affinitású PD-1 hatóanyag és alkalmazási módszerek HUE050406T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462035316P 2014-08-08 2014-08-08
US201562150789P 2015-04-21 2015-04-21

Publications (1)

Publication Number Publication Date
HUE050406T2 true HUE050406T2 (hu) 2020-12-28

Family

ID=55264785

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15829652A HUE050406T2 (hu) 2014-08-08 2015-08-07 Nagy affinitású PD-1 hatóanyag és alkalmazási módszerek

Country Status (13)

Country Link
US (5) US10800830B2 (hu)
EP (2) EP3699189A1 (hu)
JP (1) JP6945444B2 (hu)
CN (1) CN107108707A (hu)
CA (1) CA2994927A1 (hu)
CY (1) CY1123385T1 (hu)
DK (1) DK3177640T3 (hu)
ES (1) ES2819451T3 (hu)
HR (1) HRP20201153T1 (hu)
HU (1) HUE050406T2 (hu)
PL (1) PL3177640T3 (hu)
PT (1) PT3177640T (hu)
WO (1) WO2016022994A2 (hu)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10800830B2 (en) 2014-08-08 2020-10-13 The Board Of Trustees Of The Leland Stanford Junior University High affinity PD-1 agents and methods of use
CN107074952B (zh) 2014-09-30 2021-04-09 英特维特国际股份有限公司 结合犬pd-l1的pd-l1抗体
CA2968961A1 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Methods and compositions for 18f-radiolabeling of biologics
EA037590B1 (ru) 2014-11-25 2021-04-19 Бристол-Майерс Сквибб Компани Связывающиеся с pd-l1 полипептиды на основе 10fn3 домена для визуализации
CN107073138B (zh) * 2015-03-02 2018-06-29 上海斯丹赛生物技术有限公司 降低由pd-l1诱导的免疫耐受性
US11319359B2 (en) 2015-04-17 2022-05-03 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
IL255697B2 (en) 2015-05-18 2023-11-01 Tcr2 Therapeutics Inc Compositions and methods for TCR programming using fusion proteins
MX2018000621A (es) 2015-07-13 2018-05-11 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos.
EP3322448A4 (en) 2015-07-16 2019-03-06 Bioxcel Therapeutics, Inc. NOVEL METHOD FOR THE TREATMENT OF CANCER WITH IMMUNOMODULATION
RU2020143675A (ru) 2015-08-07 2021-05-26 ЭйЭлЭкс Онколоджи Инк. Конструкции, имеющие sirp-альфа домен или его вариант
CA2999756A1 (en) 2015-09-24 2017-03-30 The University Of North Carolina At Chapel Hill Methods and compositions for reducing metastases
BR112018070934A2 (pt) 2016-04-15 2019-02-26 Alpine Immune Sciences, Inc. proteínas imunomoduladoras variantes ligantes de icos e usos das mesmas
IL310729A (en) 2016-04-15 2024-04-01 Alpine Immune Sciences Inc Immunomodulatory proteins that are variants of CD80 and their uses
US11352413B2 (en) * 2016-05-17 2022-06-07 Albert Einstein College Of Medicine Engineered PD-1 variants
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
WO2017210302A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Pet imaging with pd-l1 binding polypeptides
RU2656181C1 (ru) * 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
EP3497134A4 (en) 2016-08-11 2020-01-15 The Council of the Queensland Institute of Medical Research IMMUNE MODULATION COMPOUNDS
WO2018067361A1 (en) * 2016-10-04 2018-04-12 The Curators Of The University Of Missouri Peptides for molecular detection of pd-l1
BR112019007100A2 (pt) 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
PT3535298T (pt) 2016-11-02 2021-11-25 Jounce Therapeutics Inc Anticorpos para pd-1 e seu uso
CA3043329A1 (en) 2016-11-09 2018-05-17 Healthtell Inc. Coatings with tunable amine density
WO2018098365A2 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CA3045466A1 (en) 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
AU2018205888B2 (en) 2017-01-05 2021-09-02 Kahr Medical Ltd. A PD1-41BBL fusion protein and methods of use thereof
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
AU2018205890B2 (en) 2017-01-05 2021-09-02 Kahr Medical Ltd. A sirpalpha-41BBL fusion protein and methods of use thereof
AU2018219226A1 (en) 2017-02-07 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
SG11201907208XA (en) 2017-02-10 2019-09-27 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
CN110582288A (zh) 2017-02-28 2019-12-17 恩多塞特公司 用于car t细胞疗法的组合物和方法
AU2018235838B2 (en) 2017-03-16 2023-12-14 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
AU2018235835A1 (en) 2017-03-16 2019-09-05 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
BR112019020386A2 (pt) * 2017-03-28 2020-06-09 Mayo Found Medical Education & Res vacinas de peptídeos de pd-1 humana e usos das mesmas
WO2018192443A1 (zh) * 2017-04-17 2018-10-25 中国科学院苏州纳米技术与纳米仿生研究所 一种多肽及其应用
CA3060443A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
JP2020521759A (ja) * 2017-05-26 2020-07-27 ザ・ジョンズ・ホプキンス・ユニバーシティ 免疫トレランスを調節するための多機能性の抗体−リガンド・トラップ
SG11202000073XA (en) 2017-07-24 2020-02-27 Regeneron Pharma Anti-cd8 antibodies and uses thereof
US20200206344A1 (en) * 2017-08-21 2020-07-02 Dana-Farber Cancer Institute, Inc. Methods for modulating the interaction between ews-fli1 and baf complexes
CA3077509A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
AU2018351006A1 (en) 2017-10-18 2020-05-07 Forty Seven, Inc. Anti-CD47 agent-based ovarian cancer therapy
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
CN107916255B (zh) * 2017-11-16 2021-06-04 复旦大学 Pdl-1基因靶向特异性甲基化表观遗传修饰抗肿瘤分子及其用途
US11779602B2 (en) 2018-01-22 2023-10-10 Endocyte, Inc. Methods of use for CAR T cells
CN108794619B (zh) * 2018-05-31 2021-09-17 郑州大学 一种高亲和pd-1蛋白突变体
WO2019227490A1 (en) * 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
CN112533952B (zh) 2018-06-01 2023-03-07 大有华夏生物医药集团有限公司 治疗疾病或病况的组合物及其用途
CA3104778A1 (en) * 2018-07-11 2020-01-16 Kahr Medical Ltd. Pd1-4-1bbl variant fusion protein and methods of use thereof
JP7491495B2 (ja) 2018-07-11 2024-05-28 カール メディカル リミテッド ＳＩＲＰα－４－１ＢＢＬバリアント融合タンパク質及びその使用方法
CN108997492B (zh) * 2018-07-19 2022-04-12 海珂分子（北京）科技有限责任公司 高亲和力的pd1胞外区突变体多肽及相关融合蛋白
NZ774126A (en) * 2018-09-14 2023-05-26 Akso Biopharmaceutical Inc Spd-1 variant - fc fusion proteins
WO2020102365A1 (en) * 2018-11-14 2020-05-22 Healthtell Inc. Methods of selecting functional interface mimics, and compositions thereof
JP7319368B2 (ja) 2018-11-21 2023-08-01 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ アデノウイルスおよびアデノウイルスを使用するための方法
CN111100199B (zh) * 2018-12-29 2021-02-12 北京百普赛斯生物科技股份有限公司 一种荧光素标记的蛋白四聚体及其制备方法与应用
CN111714618A (zh) * 2019-03-22 2020-09-29 广东香雪精准医疗技术有限公司 T细胞和高亲和力pd-1融合蛋白的组合
CN110054701B (zh) * 2019-04-17 2022-12-27 中国医学科学院血液病医院（血液学研究所） 一种基于间充质干细胞的抗肿瘤靶向给药***及其应用
BR112021021683A2 (pt) 2019-04-29 2021-12-21 Mayo Found Medical Education & Res Compostos multivalentes de ligação a pd-l1 para tratar câncer
MX2021013223A (es) 2019-05-01 2022-02-17 Juno Therapeutics Inc Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos.
AU2020265741A1 (en) 2019-05-01 2021-11-25 Editas Medicine, Inc. Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
SG11202112733XA (en) 2019-05-31 2021-12-30 Alx Oncology Inc Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
CN112279922B (zh) * 2019-07-22 2023-07-28 南京助天中科科技发展有限公司 一种吞噬细胞嵌合抗原受体及其应用
AU2020381514A1 (en) * 2019-11-14 2022-06-02 Ludwig Institute For Cancer Research Ltd Compositions and methods for immunotherapy
WO2021225378A1 (ko) * 2020-05-06 2021-11-11 고려대학교 산학협력단 Pd-l1 친화도가 증가된 pd-1 변이체
KR102623161B1 (ko) * 2020-10-08 2024-01-09 고려대학교 산학협력단 Pd-l1 친화도가 증가된 pd-1 변이체
WO2021260186A1 (en) 2020-06-26 2021-12-30 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
WO2022104043A1 (en) * 2020-11-13 2022-05-19 Ludwig Institute For Cancer Research Ltd Pd-1 decoy variants for immunotherapy
CN112999368A (zh) * 2021-04-09 2021-06-22 广东药康生物科技有限公司 人源化模型进行药效评价方法的建立
WO2023097313A1 (en) * 2021-11-26 2023-06-01 Vita Therapeutics, Inc. Immune cell therapy of pd-l1 positive cancers
CN117777303A (zh) * 2022-09-27 2024-03-29 北京大学 一种高亲和力pd1蛋白偶联物及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
EP0648271B1 (en) 1991-08-20 2003-04-16 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
ATE314482T1 (de) 1993-10-25 2006-01-15 Canji Inc Rekombinante adenoviren-vektor und verfahren zur verwendung
CA2143491C (en) * 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
EP1083231A1 (en) 1999-09-09 2001-03-14 Introgene B.V. Smooth muscle cell promoter and uses thereof
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7169874B2 (en) 2001-11-02 2007-01-30 Bausch & Lomb Incorporated High refractive index polymeric siloxysilane compositions
CA3201163A1 (en) * 2005-07-01 2007-01-11 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
PL2350129T3 (pl) * 2008-08-25 2015-12-31 Amplimmune Inc Kompozycje antagonistów PD-1 i sposoby stosowania
EA201170375A1 (ru) 2008-08-25 2012-03-30 Эмплиммьюн, Инк. Антагонисты pd-1 и способы их применения
WO2010063011A2 (en) 2008-11-28 2010-06-03 Emory University Methods for the treatment of infections and tumors
US20110189743A1 (en) * 2009-10-06 2011-08-04 Bio Architecture Lab, Inc. Microbial systems for producing commodity chemicals
CN107090029B (zh) 2010-11-11 2021-07-13 港大科桥有限公司 可溶性 pd-1变体、融合构建体及其用途
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
RU2625034C2 (ru) * 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
KR20190133790A (ko) * 2011-08-01 2019-12-03 제넨테크, 인크. Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
US8956619B2 (en) * 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
CN104136037B (zh) 2012-01-17 2018-02-23 小利兰·斯坦福大学托管委员会 高亲和力SIRP‑α试剂
WO2013112986A1 (en) * 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
EP3276000A3 (en) 2012-05-25 2018-02-21 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
CN104936982B (zh) 2012-08-03 2020-04-24 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
WO2014055668A1 (en) 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
DK3575326T3 (da) 2012-12-17 2022-05-30 Pf Argentum Ip Holdings Llc Behandling af CD47+ sygdomsceller med SIRP ALFA-FC-fusioner
US20150368316A1 (en) 2013-02-07 2015-12-24 Albert Einstein College Of Medicine Of Yeshiva University A selective high-affinity immune stimulatory reagent and uses thereof
CN105874061B (zh) 2013-02-26 2021-08-10 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
US10800830B2 (en) * 2014-08-08 2020-10-13 The Board Of Trustees Of The Leland Stanford Junior University High affinity PD-1 agents and methods of use
EP3298043B8 (en) * 2015-05-18 2021-04-21 AB Initio Biotherapeutics, Inc. Sirp polypeptide compositions and methods of use

Also Published As

Publication number Publication date
US10800830B2 (en) 2020-10-13
US20160052990A1 (en) 2016-02-25
CA2994927A1 (en) 2016-02-11
JP2017525354A (ja) 2017-09-07
CY1123385T1 (el) 2021-12-31
EP3699189A1 (en) 2020-08-26
EP3177640A2 (en) 2017-06-14
US20170233451A1 (en) 2017-08-17
US9562087B2 (en) 2017-02-07
US9546206B2 (en) 2017-01-17
WO2016022994A9 (en) 2017-05-11
PT3177640T (pt) 2020-08-31
US20210040176A1 (en) 2021-02-11
US20240174729A1 (en) 2024-05-30
JP6945444B2 (ja) 2021-10-06
HRP20201153T1 (hr) 2021-01-22
PL3177640T3 (pl) 2020-11-02
EP3177640B1 (en) 2020-05-06
ES2819451T3 (es) 2021-04-16
WO2016022994A3 (en) 2016-05-06
WO2016022994A2 (en) 2016-02-11
DK3177640T3 (da) 2020-08-10
CN107108707A (zh) 2017-08-29
EP3177640A4 (en) 2018-01-03
US20160039903A1 (en) 2016-02-11
US11814419B2 (en) 2023-11-14

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
PL3177640T3 (pl) Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania
IL250415B (en) Antibodies against pd-l and methods of using them
HK1243102A1 (zh) 抗cd79b抗體和使用方法
HRP20181359T1 (hr) Anti-jagged1 protutijela i postupci uporabe
IL251868A0 (en) Anti-tim3 antibodies and methods of use
HK1253049A1 (zh) 糖基相互作用化合物及其使用方法
IL251988A0 (en) Compounds acting on glycans and methods of using them
IL251165A0 (en) Anti-il-1beta antibodies and methods of their use
ZA201701909B (en) Trichoderma compositions and methods of use
SG11201708114SA (en) Ophthalmic compositions and methods of use therefor
PL3089971T3 (pl) Związki i sposoby ich zastosowania
IL251286A0 (en) Anti-pdgf-b antibodies and methods of use
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
ZA201606450B (en) Compounds and their methods of use
HK1243404A1 (zh) 色酰胺組合物和使用方法
GB201403697D0 (en) Compounds and methods of use
GB201416797D0 (en) Contianer and method of use thereof